<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2025-3-41-48</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-2630</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of intravenous thrombolytic therapy in patients with ischemic stroke and mild neurological deficit</article-title><trans-title-group xml:lang="ru"><trans-title>Эффективность и безопасность внутривенной тромболитической терапии у пациентов с ишемическим инсультом с легким неврологическим дефицитом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-8680-4928</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сулейманова</surname><given-names>М. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Suleymanova</surname><given-names>M. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мадина Ринатовна Сулейманова</p><p>420012, Казань, ул. Бутлерова, 49</p><p> </p></bio><bio xml:lang="en"><p>Madina Rinatovna Suleymanova</p><p>49, Butlerova St., Kazan 420012</p></bio><email xlink:type="simple">almafari@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6926-6155</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Данилова</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Danilova</surname><given-names>T. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>420012, Казань, ул. Бутлерова, 49</p><p>420101, Казань, ул. Карбышева, 12а</p></bio><bio xml:lang="en"><p>49, Butlerova St., Kazan 420012</p><p>12a, Karbysheva St., Kazan 420101</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8825-2346</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хасанова</surname><given-names>Д. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Khasanova</surname><given-names>D. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>420012, Казань, ул. Бутлерова, 49</p><p>420101, Казань, ул. Карбышева, 12а</p></bio><bio xml:lang="en"><p>49, Butlerova St., Kazan 420012</p><p>12a, Karbysheva St., Kazan 420101</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России; ГАУЗ «Межрегиональный клинико-диагностический центр»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan State Medical University, Ministry of Health of Russia; Interregional Clinical and Diagnostic Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>24</day><month>06</month><year>2025</year></pub-date><volume>17</volume><issue>3</issue><fpage>41</fpage><lpage>48</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Suleymanova M.R., Danilova T.V., Khasanova D.R., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Сулейманова М.Р., Данилова Т.В., Хасанова Д.Р.</copyright-holder><copyright-holder xml:lang="en">Suleymanova M.R., Danilova T.V., Khasanova D.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/2630">https://nnp.ima-press.net/nnp/article/view/2630</self-uri><abstract><p>Intravenous thrombolytic therapy (IV TLT) is the main method of reperfusion therapy for ischemic stroke (IS). Almost half of IS patients present with a mild neurological deficit at onset, for which the efficacy of IV TLT remains controversial.</p><sec><title>Objective</title><p>Objective: to assess the efficacy and safety of IV TLT in patients with IS and mild neurological deficit depending on the degree of stenosis of the main arteries of the head (MAH), regardless of the level of disability.</p></sec><sec><title>Material and methods</title><p>Material and methods. A total of 166 patients with IS and mild neurological deficit (less than 5 points on the NIHSS stroke severity scale) were observed: 82 patients received IV TLT, and 84 patients formed the comparison group.</p></sec><sec><title>Results</title><p>Results. At hospital discharge, IS patients who received IV TLT showed a lower severity of neurological deficit on the NIHSS scale (U(82,84)=1882; p&lt;0.001) and a better functional outcome according to the modified Rankin Scale (U(82,84)=1854; p&lt;0.001) and the Rivermead Mobility Index (U(82,84)=1795; p&lt;0.001). In the subgroup of patients with significant MAH stenosis, statistically significant advantages of IV TLT were also found according the NIHSS, Rankin Scale, and Rivermead Index. Hemorrhagic transformations occurred in the IV TLT group in 14 patients, and in the comparison group in 6 patients (only a trend toward increased frequency).</p></sec><sec><title>Conclusion</title><p>Conclusion. IV TLT in patients with IS and mild neurological deficit improves functional outcomes in the acute period of stroke. IV TLT is also effective in the subgroup of patients with significant MAH stenosis.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Внутривенная тромболитическая терапия (ВВ ТЛТ) – основной метод реперфузионной терапии ишемического инсульта (ИИ). Почти у половины пациентов с ИИ в дебюте развивается легкий неврологический дефицит, при котором эффективность ВВ ТЛТ остается дискуссионной.</p><p>Цель исследования – оценить эффективность и безопасность ВВ ТЛТ у пациентов с ИИ и легким неврологическим дефицитом в зависимости от степени стеноза магистральных артерий головы (МАГ) независимо от степени инвалидизации.</p><sec><title>Материал и методы</title><p>Материал и методы. Наблюдались 166 пациентов с ИИ с легким неврологическим дефицитом (менее 5 баллов по шкале тяжести инсульта NIHSS): 82 пациентам была проведена ВВ ТЛТ, 84 пациента составили группу сравнения.</p></sec><sec><title>Результаты</title><p>Результаты. На момент выписки из стационара пациенты с ИИ, которым была выполнена ВВ ТЛТ, имели меньшую выраженность неврологического дефицита по NIHSS (U(82,84)=1882; p&lt;0,001) и лучший функциональный исход по Модифицированной шкале Рэнкина (U(82,84)=1854; p&lt;0,001) и по Индексу мобильности Ривермид (U(82,84)=1795; p&lt;0,001). В подгруппе пациентов со значимыми стенозами МАГ также выявлены статистически значимые преимущества проведения ВВ ТЛТ по NIHSS, Модифицированной шкале Рэнкина и Индексу мобильности Ривермид. Геморрагические трансформации возникли в группе с ВВ ТЛТ у 14 пациентов, в группе сравнения – у шести пациентов (только тенденция к учащению).</p></sec><sec><title>Заключение</title><p>Заключение. Проведение ВВ ТЛТ у пациентов с ИИ и легким неврологическим дефицитом улучшает функциональный исход в остром периоде инсульта. ВВ ТЛТ также эффективна в подгруппе пациентов с наличием значимых стенозов МАГ.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ишемический инсульт</kwd><kwd>легкий неврологический дефицит</kwd><kwd>внутривенная тромболитическая терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ischemic stroke</kwd><kwd>mild neurological deficit</kwd><kwd>intravenous thrombolytic therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Алашеев АМ, Белкин АА, Богатырева МД, редакторы. Протокол тромболитической терапии острого ишемического инсульта. Санкт-Петербург; 2023. 52 с.</mixed-citation><mixed-citation xml:lang="en">Alasheev AM, Belkin AA, BogatyrevaMD, editors. Protocol of thrombolytic therapy for acute ischemic stroke. St. Petersburg; 2023. 52 p. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Merlino G, Nesi L, Vergobbi P, et al. The use of alteplase, although safe, does not offer clear clinical advantages when mild stroke is non-disabling. Front Neurol. 2023 Jul 17;14:1212712. doi: 10.3389/fneur.2023.1212712</mixed-citation><mixed-citation xml:lang="en">Merlino G, Nesi L, Vergobbi P, et al. The use of alteplase, although safe, does not offer clear clinical advantages when mild stroke is non-disabling. Front Neurol. 2023 Jul 17;14:1212712. doi: 10.3389/fneur.2023.1212712</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Sykora M, Krebs S, Simader F, et al; Austrian Stroke Unit Registry Collaborators. Intravenous thrombolysis in stroke with admission NIHSS score 0 or 1. Int J Stroke. 2022 Jan;17(1):109-19. doi: 10.1177/1747493021991969. Epub 2021 Feb 10.</mixed-citation><mixed-citation xml:lang="en">Sykora M, Krebs S, Simader F, et al; Austrian Stroke Unit Registry Collaborators. Intravenous thrombolysis in stroke with admission NIHSS score 0 or 1. Int J Stroke. 2022 Jan;17(1):109-19. doi: 10.1177/1747493021991969. Epub 2021 Feb 10.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Khatri P, Conaway MR, Johnston KC; Acute Stroke Accurate Prediction Study (ASAP) Investigators. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. Stroke. 2012 Feb;43(2):560-2. doi: 10.1161/STROKEAHA.110.593897. Epub 2011 Nov 3.</mixed-citation><mixed-citation xml:lang="en">Khatri P, Conaway MR, Johnston KC; Acute Stroke Accurate Prediction Study (ASAP) Investigators. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. Stroke. 2012 Feb;43(2):560-2. doi: 10.1161/STROKEAHA.110.593897. Epub 2011 Nov 3.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ali SF, Siddiqui K, Ay H, et al. Baseline Predictors of Poor Outcome in Patients Too Good to Treat With Intravenous Thrombolysis. Stroke. 2016 Dec;47(12):2986-92. doi: 10.1161/STROKEAHA.116.014871. Epub 2016 Nov 10.</mixed-citation><mixed-citation xml:lang="en">Ali SF, Siddiqui K, Ay H, et al. Baseline Predictors of Poor Outcome in Patients Too Good to Treat With Intravenous Thrombolysis. Stroke. 2016 Dec;47(12):2986-92. doi: 10.1161/STROKEAHA.116.014871. Epub 2016 Nov 10.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Chen HS, Cui Y, Zhou ZH, et al; ARAMIS Investigators. Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial. JAMA. 2023 Jun 27;329(24):2135-44. doi: 10.1001/jama.2023.7827</mixed-citation><mixed-citation xml:lang="en">Chen HS, Cui Y, Zhou ZH, et al; ARAMIS Investigators. Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial. JAMA. 2023 Jun 27;329(24):2135-44. doi: 10.1001/jama.2023.7827</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021 Mar;6(1):I-LXII. doi: 10.1177/2396987321989865. Epub 2021 Feb 19.</mixed-citation><mixed-citation xml:lang="en">Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021 Mar;6(1):I-LXII. doi: 10.1177/2396987321989865. Epub 2021 Feb 19.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Всероссийское общество неврологов, Национальная ассоциация по борьбе с инсультом, Ассоциация нейрохирургов России, Межрегиональная общественная организация «Объединение нейроанестезиологов и нейрореаниматологов», Общероссийская общественная организация «Союз реабилитологов России» Клинические рекомендации. Ишемический инсульт и транзиторная ишемическая атака у взрослых. 2024. Доступно по ссылке: https://cr.minzdrav.gov.ru/preview-cr/814_1 (дата обращения 30.01.2025)</mixed-citation><mixed-citation xml:lang="en">All-Russian Society of Neurologists, National Association for Stroke Control, Association of Neurosurgeons of Russia, IPO “Association of Neuroanesthesiologists and Neurointensivists”, Union of Rehabilitologists of Russia. Clinical recommendations. Ischemic stroke and transient ischemic attack in adults. 2024. Available at: https://cr.minzdrav.gov.ru/preview-cr/814_1 (accessed 30.01.2025 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Powers WJ, Rabinstein AA, Ackerson T, et al; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-e110. doi: 10.1161/STR.0000000000000158. Epub 2018 Jan 24. Erratum in: Stroke. 2018 Mar;49(3):e138. doi: 10.1161/STR.0000000000000163. Erratum in: Stroke. 2018 Jun;49(6):e233-e234. doi: 10.1161/STR.0000000000000172</mixed-citation><mixed-citation xml:lang="en">Powers WJ, Rabinstein AA, Ackerson T, et al; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-e110. doi: 10.1161/STR.0000000000000158. Epub 2018 Jan 24. Erratum in: Stroke. 2018 Mar;49(3):e138. doi: 10.1161/STR.0000000000000163. Erratum in: Stroke. 2018 Jun;49(6):e233-e234. doi: 10.1161/STR.0000000000000172</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Seners P, Perrin C, Lapergue B, et al; MINOR-STROKE Collaborators. Bridging Therapy or IV Thrombolysis in Minor Stroke with Large Vessel Occlusion. Ann Neurol. 2020 Jul;88(1):160-9. doi: 10.1002/ana.25756. Epub 2020 May 14.</mixed-citation><mixed-citation xml:lang="en">Seners P, Perrin C, Lapergue B, et al; MINOR-STROKE Collaborators. Bridging Therapy or IV Thrombolysis in Minor Stroke with Large Vessel Occlusion. Ann Neurol. 2020 Jul;88(1):160-9. doi: 10.1002/ana.25756. Epub 2020 May 14.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Adams HP Jr, Bendixen BH, Kappelle LJ,et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993 Jan;24(1):35-41. doi: 10.1161/01.str.24.1.35</mixed-citation><mixed-citation xml:lang="en">Adams HP Jr, Bendixen BH, Kappelle LJ,et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993 Jan;24(1):35-41. doi: 10.1161/01.str.24.1.35</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Khatri P, Kleindorfer DO, Devlin T, et al;PRISMS Investigators. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. JAMA. 2018 Jul 10;320(2):156-66. doi: 10.1001/jama.2018.8496</mixed-citation><mixed-citation xml:lang="en">Khatri P, Kleindorfer DO, Devlin T, et al;PRISMS Investigators. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. JAMA. 2018 Jul 10;320(2):156-66. doi: 10.1001/jama.2018.8496</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Braksick SA, Rabinstein AA. ThrombolysisIs Not Indicated for Minor Strokes If They Are Truly Nondisabling. Stroke. 2024 Apr;55(4):893-4. doi: 10.1161/STROKEA-HA.124.046549</mixed-citation><mixed-citation xml:lang="en">Braksick SA, Rabinstein AA. ThrombolysisIs Not Indicated for Minor Strokes If They Are Truly Nondisabling. Stroke. 2024 Apr;55(4):893-4. doi: 10.1161/STROKEA-HA.124.046549</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Marsh EB, Girgenti S, Llinas EJ, Brunson AO. Outcomes in Patients with Minor Stroke: Diagnosis and Management in the Post-thrombectomy Era. Neurotherapeutics. 2023 Apr;20(3):732-43. doi: 10.1007/s13311-023-01349-5. Epub 2023 Feb 8.</mixed-citation><mixed-citation xml:lang="en">Marsh EB, Girgenti S, Llinas EJ, Brunson AO. Outcomes in Patients with Minor Stroke: Diagnosis and Management in the Post-thrombectomy Era. Neurotherapeutics. 2023 Apr;20(3):732-43. doi: 10.1007/s13311-023-01349-5. Epub 2023 Feb 8.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Yaghi S, Willey JZ, Khatri P. Minorischemic stroke: Triaging, disposition, and outcome. Neurol Clin Pract. 2016 Apr;6(2):157-63. doi: 10.1212/CPJ.0000000000000234</mixed-citation><mixed-citation xml:lang="en">Yaghi S, Willey JZ, Khatri P. Minorischemic stroke: Triaging, disposition, and outcome. Neurol Clin Pract. 2016 Apr;6(2):157-63. doi: 10.1212/CPJ.0000000000000234</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Alhazzani A, Al-Ajlan FS, Alkhiri A, et al.Intravenous alteplase in minor nondisabling ischemic stroke: A systematic review and metaanalysis. Eur Stroke J. 2024 Sep;9(3):521-9. doi: 10.1177/23969873241237312. Epub 2024 Mar 11.</mixed-citation><mixed-citation xml:lang="en">Alhazzani A, Al-Ajlan FS, Alkhiri A, et al.Intravenous alteplase in minor nondisabling ischemic stroke: A systematic review and metaanalysis. Eur Stroke J. 2024 Sep;9(3):521-9. doi: 10.1177/23969873241237312. Epub 2024 Mar 11.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Cui Y, He C, Li ZA, et al. Dual Antiplatelet Versus Alteplase for Early Neurologic Deterioration in Minor Stroke With Versus Without Large Vessel Occlusion: Prespecified Post Hoc Analysis of the ARAMIS Trial. Stroke. 2024 Nov;55(11):2590-8. doi: 10.1161/STROKEAHA.124.048248. Epub 2024 Oct 10. 18. Tsivgoulis G, Goyal N, Katsanos AH, et al. Intravenous thrombolysis for large vessel or distal occlusions presenting with mild stroke severity. Eur J Neurol. 2020 Jun;27(6):1039-47. doi: 10.1111/ene.14199. Epub 2020 Mar 23.</mixed-citation><mixed-citation xml:lang="en">Cui Y, He C, Li ZA, et al. Dual Antiplatelet Versus Alteplase for Early Neurologic Deterioration in Minor Stroke With Versus Without Large Vessel Occlusion: Prespecified Post 	Hoc Analysis of the ARAMIS Trial. Stroke. 2024 Nov;55(11):2590-8. doi: 10.1161/STROKEAHA.124.048248. Epub 2024 Oct 10.	18. Tsivgoulis G, Goyal N, Katsanos AH, et al. Intravenous thrombolysis for large vessel or distal occlusions presenting with mild stroke severity. Eur J Neurol. 2020 Jun;27(6):1039-47. doi: 10.1111/ene.14199. Epub 2020 Mar 23.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
